TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23828615

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 22810046

Group type: EXPERIMENTAL
Intervention: Functional interactivity in eHealth application
Number of subjects: 165
Study: 19409693

Group type: EXPERIMENTAL
Intervention: Tadalafil 2.5 mg
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 581

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Tadalafil (all doses)
Number of subjects: 581
Study: 17103169

Group type: EXPERIMENTAL
Intervention: Immunochemotherapy (Rituximab 375 mg/m² with intensified salvage chemotherapy)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Chemotherapy (without Rituximab)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Immunochemotherapy
Number of subjects: 67

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 67
Study: 15188945

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 102

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 102
Study: 11384787

Group type: EXPERIMENTAL
Intervention: Net health benefit analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Varying willingness-to-pay values
Number of subjects: 0
Study: 9699400

Group type: EXPERIMENTAL
Intervention: Fluor Protector applied before band cementation with glass ionomer cement
Number of subjects: 18

Group type: COMPARATOR
Intervention: Glass ionomer cement without Fluor Protector (control group)
Number of subjects: 18
Study: 9431262

Group type: EXPERIMENTAL
Intervention: Square-shaped wrist
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Abductor pollicis brevis weakness
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Median nerve hypesthesia
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Phalen sign
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Median nerve compression sign
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Hoffmann-Tinel sign
Number of subjects: 143
Study: 1822438

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg BID
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6813485

Group type: EXPERIMENTAL
Intervention: Auranofin (AF)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Gold sodium thiomalate
Number of subjects: 39

Group type: COMPARATOR
Intervention: D-penicillamine
Number of subjects: 39
Study: 31877062

Group type: EXPERIMENTAL
Intervention: Hard shoes
Number of subjects: 848

Group type: COMPARATOR
Intervention: Soft shoes
Number of subjects: 848
Study: 30682333

Group type: EXPERIMENTAL
Intervention: Beetroot juice supplementation (seven daily doses)
Number of subjects: 76

Group type: COMPARATOR
Intervention: No supplementation (control)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Beetroot juice supplementation
Number of subjects: 76
Study: 26763612

Group type: EXPERIMENTAL
Intervention: Herbal saliva substitute (chamomile and linseed)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Conventional saliva substitute (carboxymethyl cellulose)
Number of subjects: 74
Study: 25596344

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 23733668

Group type: EXPERIMENTAL
Intervention: isoflurane + dexmedetomidine (group DISO)
Number of subjects: 60

Group type: COMPARATOR
Intervention: isoflurane + saline (group NISO)
Number of subjects: 60
Study: 21708030

Group type: EXPERIMENTAL
Intervention: eGFR below 60 ml/min/1.73 m²
Number of subjects: 6653

Group type: COMPARATOR
Intervention: eGFR normal
Number of subjects: 6653

Group type: EXPERIMENTAL
Intervention: eGFR
Number of subjects: 6653

Group type: EXPERIMENTAL
Intervention: se-creatinine
Number of subjects: 6653
Study: 17591648

Group type: EXPERIMENTAL
Intervention: PUFA (Arachidonic acid 240 mg/day, Docosahexaenoic acid 240 mg/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 16548864

Group type: EXPERIMENTAL
Intervention: Bupivacaine plus 2 microg/kg of clonidine
Number of subjects: 60
Study: 12948063

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 10989853

Group type: EXPERIMENTAL
Intervention: Intubating Laryngeal Mask Airway (ILMA) with Normal curved tracheal tube
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Intubating Laryngeal Mask Airway (ILMA) with Reverse curved tracheal tube
Number of subjects: 240
Study: 8891657

Group type: EXPERIMENTAL
Intervention: Cloud display (parallax and expansion congruent)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other displays (hallway, side walls, ground surface, wall, wall with central hole, hall farther, wall farther)
Number of subjects: 0
Study: 1857725

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (3 g as Ca/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low-Calcium diet (163 +/- 1 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal Calcium intake (536 +/- 2 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Calcium deprivation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Calcium loading
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low and high Ca intake
Number of subjects: 12
Study: 6342770

Group type: EXPERIMENTAL
Intervention: MCP (100 mg) plus dexamethasone (DM; 48 mg) iv
Number of subjects: 26

Group type: COMPARATOR
Intervention: MCP (100 mg) plus placebo
Number of subjects: 26
Study: 30379348

Group type: EXPERIMENTAL
Intervention: Dampness and mold exposure (including signs such as mold, damp stains, damp bed clothing, water damage, window pane condensation, mold odor, humid air)
Number of subjects: 36541

Group type: EXPERIMENTAL
Intervention: Mold odor
Number of subjects: 36541

Group type: EXPERIMENTAL
Intervention: Humid air
Number of subjects: 36541
Study: 28299831

Group type: EXPERIMENTAL
Intervention: Ageratina pichinchensis extract (7% standardized, intravaginally administered for 6 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clotrimazole (100 mg, positive control)
Number of subjects: 0
Study: 26755682

Group type: EXPERIMENTAL
Intervention: Frailty Index (FI) classification
Number of subjects: 9306
Study: 23529834

Group type: EXPERIMENTAL
Intervention: Compound Phyllanthus Urinaria L. (CPUL) for 3 years
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 102
Study: 21739267

Group type: EXPERIMENTAL
Intervention: Coadministration of paroxetine (20 mg/day) with aripiprazole (3 mg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Coadministration of fluvoxamine (100 mg/day) with aripiprazole (3 mg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: CYP2D6 EMs with paroxetine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: CYP2D6 IMs with paroxetine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: CYP2D6 EMs with fluvoxamine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: CYP2D6 IMs with fluvoxamine
Number of subjects: 28
Study: 19125322

Group type: EXPERIMENTAL
Intervention: Letrozole for 6 months
Number of subjects: 42
Study: 17970679

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate rinsing
Number of subjects: 20
Study: 14726421

Group type: EXPERIMENTAL
Intervention: Protocol weaning
Number of subjects: 299

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 299
Study: 12230023

Group type: EXPERIMENTAL
Intervention: Kakkon-to (7.5 g daily for 3 days before surgery, the day of surgery, and for 7 days after surgery)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Sairei-to (9.0 g daily for 3 days before surgery, the day of surgery, and for 7 days after surgery)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Untreated right eyes (control group)
Number of subjects: 27
Study: 9718972

Group type: EXPERIMENTAL
Intervention: Cetirizine 5 mg (for children weighing less than 30 kg) or 10 mg (for children weighing more than 30 kg) once daily for 15 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Levocabastine 2 puffs BID on each nostril for 15 days
Number of subjects: 30
Study: 7638127

Group type: EXPERIMENTAL
Intervention: Isoproterenol sensitized head-up tilt test (bolus of isoproterenol 2, 4, 6 and 8 micrograms starting 30 minutes after the beginning of the test)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-sensitized head-up tilt test (no presensitization)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-sensitized head-up tilt test
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isoproterenol sensitized head-up tilt test
Number of subjects: 30
Study: 2512632

Group type: EXPERIMENTAL
Intervention: Ranitidine (dosing at early evening)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nizatidine (dosing at early evening)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (dosing at early evening)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine (dosing at nighttime)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nizatidine (dosing at nighttime)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (dosing at nighttime)
Number of subjects: 0
Study: 4613503

Group type: EXPERIMENTAL
Intervention: WR 33 063
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: WR 30 090
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other compounds
Number of subjects: 0
Study: 30967148

Group type: EXPERIMENTAL
Intervention: Artefenomel (OZ439) - piperaquine (PPQ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29178923

Group type: EXPERIMENTAL
Intervention: Guided self-determination-young (GSD-Y) intervention with seven individual education visits over 3 to 6 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care including regular visits to the diabetes clinic
Number of subjects: 100
Study: 26138546

Group type: EXPERIMENTAL
Intervention: High-Efficiency Online Hemodiafiltration (HDF)
Number of subjects: 72

Group type: COMPARATOR
Intervention: High-Flux Dialysis (HF)
Number of subjects: 72
Study: 23375965

Group type: EXPERIMENTAL
Intervention: 0.4 g intravenous immunoglobulin per kg every 2 weeks
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 0.2 g intravenous immunoglobulin per kg every 4 weeks
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 0.5 g intravenous immunoglobulin per kg every 4 weeks
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 0.8 g intravenous immunoglobulin per kg every 4 weeks
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 0.1 g intravenous immunoglobulin per kg every 2 weeks
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 0.25 g intravenous immunoglobulin per kg every 2 weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 21854192

Group type: EXPERIMENTAL
Intervention: Ipragliflozin 50 mg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ipragliflozin 100 mg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ipragliflozin 200 mg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ipragliflozin 300 mg
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 19358784

Group type: EXPERIMENTAL
Intervention: Venlafaxine ER (75-225 mg/d)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study: 16476042

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - 2 mg of estradiol plus 1 mg norethisterone acetate (n = 20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Alendronate - 10 mg (n = 18)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of HRT and Alendronate (n = 22)
Number of subjects: 60
Study: 14981230

Group type: EXPERIMENTAL
Intervention: Parent-only intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Children-only intervention (Control)
Number of subjects: 50
Study: 11320385

Group type: EXPERIMENTAL
Intervention: Vi-rEPA vaccine
Number of subjects: 11091

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 11091

Group type: EXPERIMENTAL
Intervention: Vi-rEPA vaccine (1 injection)
Number of subjects: 11091

Group type: COMPARATOR
Intervention: Placebo (1 injection)
Number of subjects: 11091
Study: 9542261

Group type: EXPERIMENTAL
Intervention: Telemedicine (DIANET system)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional system
Number of subjects: 20
Study: 8515109

Group type: EXPERIMENTAL
Intervention: Albendazole (200 mg; n = 11)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (n = 12)
Number of subjects: 23
Study: 3032394

Group type: EXPERIMENTAL
Intervention: 4000 cGy continuous course
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: 4000 cGy split course
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: 5000 cGy continuous course
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: 6000 cGy continuous course
Number of subjects: 551

Group type: COMPARATOR
Intervention: Various groups
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Adenocarcinoma or large cell undifferentiated carcinoma
Number of subjects: 551

Group type: COMPARATOR
Intervention: All histologic groups
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Squamous cell carcinoma
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Adenocarcinoma
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Large cell carcinoma
Number of subjects: 551
Study: 31702699

Group type: EXPERIMENTAL
Intervention: Carbohydrate group (200 mL of apple or grape juice every 3 hours)
Number of subjects: 3984

Group type: COMPARATOR
Intervention: Fasting group (water only)
Number of subjects: 3984

Group type: EXPERIMENTAL
Intervention: Carbohydrate group
Number of subjects: 3984

Group type: COMPARATOR
Intervention: Fasting group
Number of subjects: 3984
Study: 29808711

Group type: EXPERIMENTAL
Intervention: Intensive pharmaceutical care
Number of subjects: 53

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 53
Study: 27654648

Group type: EXPERIMENTAL
Intervention: Chewing gum three times daily from day 1 until discharge
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standardized recovery programme
Number of subjects: 82
Study: 23996482

Group type: EXPERIMENTAL
Intervention: Bortezomib, adriamycin, dexamethasone (PAD)
Number of subjects: 827

Group type: COMPARATOR
Intervention: Vincristine, adriamycin, dexamethasone (VAD)
Number of subjects: 827
Study: 22883843

Group type: EXPERIMENTAL
Intervention: 0.4 NDF
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 3.0 NDF
Number of subjects: 19
Study: 20117455

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 18549685

Group type: EXPERIMENTAL
Intervention: Cetrorelix at incremental dose (0.25 mg per day increasing to 0.5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cetrorelix at high dose (0.5 mg per day)
Number of subjects: 0
Study: 12009014

Group type: EXPERIMENTAL
Intervention: Jumping intervention (10 minutes, 3 times per week)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Jumping intervention
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 121
Study: 9893076

Group type: EXPERIMENTAL
Intervention: 50 mg daily micronized DHEA
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 200 mg daily micronized DHEA
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 50 mg, 100 mg, or 200 mg daily micronized DHEA
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: DHEA therapy
Number of subjects: 15
Study: 7776164

Group type: EXPERIMENTAL
Intervention: Controlled de-epithelialization with the carbon dioxide laser at the time of flap surgery and at 10-day intervals over the first 30 days of healing.
Number of subjects: 2

Group type: COMPARATOR
Intervention: Open debridement only (control group).
Number of subjects: 2
Study: 2110411

Group type: EXPERIMENTAL
Intervention: 200 micrograms TRH
Number of subjects: 2

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 2
Study: 876324

Group type: EXPERIMENTAL
Intervention: Antacid regimen
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 30538299

Group type: EXPERIMENTAL
Intervention: 30% calorie-reduced intake diet
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Step-count device to monitor physical activity
Number of subjects: 80

Group type: COMPARATOR
Intervention: Activity advice only
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Metformin dosage reduction
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lifestyle interventions tailored to needs
Number of subjects: 80
Study: 28074788

Group type: EXPERIMENTAL
Intervention: 2 mg/kg intravenous unfractionated heparin
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 3 mg/kg intravenous unfractionated heparin
Number of subjects: 62
Study: 24988118

Group type: EXPERIMENTAL
Intervention: Daily 7000 IU vitamin D3 supplementation
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 23764912

Group type: EXPERIMENTAL
Intervention: Botox® 100 MU (B100)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Botox® 50 MU (B50)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Botox® 100 MU (B100) and Botox® 50 MU (B50)
Number of subjects: 51
Study: 21777268

Group type: EXPERIMENTAL
Intervention: Regenerative strategy applied to 25 hopeless teeth
Number of subjects: 50

Group type: COMPARATOR
Intervention: Extraction of 25 hopeless teeth and replacement with conventional or implant-supported fixed partial dentures
Number of subjects: 50
Study: 18438234

Group type: EXPERIMENTAL
Intervention: CPS (5 g Cr + 4 g phosphate)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (20 g dextrose)
Number of subjects: 32
Study: 16937604

Group type: EXPERIMENTAL
Intervention: Walking intervention (3 miles a day, 3 days a week) for 16 weeks in White exercisers (WE)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Walking intervention (3 miles a day, 3 days a week) for 16 weeks in African American exercisers (AAE)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (AAC)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (WC)
Number of subjects: 75
Study: 14516297

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 683
Study: 10868712

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (750 microg twice daily via Diskus)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Budesonide (800 microg twice daily via Turbuhaler)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP) or budesonide (1500-1600 microg day(‐1)) during run-in and washout periods
Number of subjects: 60
Study: 9195572

Group type: EXPERIMENTAL
Intervention: Flow Cytometry (FCM)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Image Cytometry (ICM)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Both ICM and FCM
Number of subjects: 104
Study: 1399547

Group type: EXPERIMENTAL
Intervention: Naproxen sodium (NPX)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Ergotamine tartrate (ERG)
Number of subjects: 79
Study: 2860157

Group type: EXPERIMENTAL
Intervention: 5% PVP‐I cream
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10% PVP‐I ointment mixed with a proteolytic agent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5% PVP‐I cream with proteolytic agent
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31168604

Group type: EXPERIMENTAL
Intervention: Remote patient monitoring (RPM) plus a yearly in-clinic ICD check-up
Number of subjects: 595

Group type: COMPARATOR
Intervention: In-clinic check-ups alone (3-6 months)
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: RPM
Number of subjects: 595
Study: 28772248

Group type: EXPERIMENTAL
Intervention: Camel Snus Winterchill and Robust (5 min trial)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Product Evaluation Scale (PES) and Drug Effects Questionnaire (DEQ) ratings
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Camel Snus (1 unit per day or at least 7 pouches total)
Number of subjects: 151
Study: 27075314

Group type: EXPERIMENTAL
Intervention: NRL001 5 mg
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: NRL001 7.5 mg
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: NRL001 10 mg
Number of subjects: 466

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: All groups (including NRL001 and placebo)
Number of subjects: 466
Study: 24588133

Group type: EXPERIMENTAL
Intervention: Immersive semester-long simulation exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Facilitated tabletop exercises
Number of subjects: 0
Study: 23163146

Group type: EXPERIMENTAL
Intervention: Acupuncture anesthesia (AA)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Local anesthesia (LA)
Number of subjects: 61
Study: 20684941

Group type: EXPERIMENTAL
Intervention: Random practice (dissimilar parameter condition)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Blocked practice (dissimilar parameter condition)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Random practice (similar parameter condition)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Blocked practice (similar parameter condition)
Number of subjects: 60
Study: 17051504

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted tipranavir (TPV/r)
Number of subjects: 863

Group type: COMPARATOR
Intervention: Ritonavir-boosted protease inhibitor (CPI/r)
Number of subjects: 863
Study: 12616120

Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation with polyethylene glycol (Group A)
Number of subjects: 380

Group type: COMPARATOR
Intervention: No mechanical bowel preparation (Group B)
Number of subjects: 380
Study: 11259932

Group type: EXPERIMENTAL
Intervention: kHz frequency alternating current (1-15 kHz, interrupted at 50 Hz, applied in 3-s surges for 10 minutes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: kHz frequency alternating current
Number of subjects: 0
Study: 10170449

Group type: EXPERIMENTAL
Intervention: Alfentanil + propofol
Number of subjects: 26

Group type: COMPARATOR
Intervention: Morphine + midazolam
Number of subjects: 26
Study: 7524379

Group type: EXPERIMENTAL
Intervention: Reogluman administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference patients (control group)
Number of subjects: 0
Study: 3091188

Group type: EXPERIMENTAL
Intervention: Ritanserin (5-HT2 antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0